Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the working group on cardio-oncology of the Korean society of echocardiography

Hyungseop Kim, Woo Baek Chung, Kyoung Im Cho, Bong Joon Kim, Jeong Sook Seo, Seong-Mi Park, Hak Jin Kim, Ju Hee Lee, Eun Kyoung Kim, Ho Joong Youn

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.

Original languageEnglish
Pages (from-to)1-25
Number of pages25
JournalJournal of Cardiovascular Ultrasound
Volume26
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Echocardiography
Drug Therapy
Neoplasms
Anthracyclines
Early Detection of Cancer
Therapeutics
Biomarkers
Morbidity
Mortality
Cardiotoxicity
Cardiologists
Oncologists

Keywords

  • Anti-cancer treatment
  • Cardio-oncology
  • Cardiovascular toxicity
  • Echocardiography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice : an opinion paper from the working group on cardio-oncology of the Korean society of echocardiography. / Kim, Hyungseop; Chung, Woo Baek; Cho, Kyoung Im; Kim, Bong Joon; Seo, Jeong Sook; Park, Seong-Mi; Kim, Hak Jin; Lee, Ju Hee; Kim, Eun Kyoung; Youn, Ho Joong.

In: Journal of Cardiovascular Ultrasound, Vol. 26, No. 1, 01.01.2018, p. 1-25.

Research output: Contribution to journalReview article

Kim, Hyungseop ; Chung, Woo Baek ; Cho, Kyoung Im ; Kim, Bong Joon ; Seo, Jeong Sook ; Park, Seong-Mi ; Kim, Hak Jin ; Lee, Ju Hee ; Kim, Eun Kyoung ; Youn, Ho Joong. / Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice : an opinion paper from the working group on cardio-oncology of the Korean society of echocardiography. In: Journal of Cardiovascular Ultrasound. 2018 ; Vol. 26, No. 1. pp. 1-25.
@article{501f40ed377d4f40bffee2ea50e15312,
title = "Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the working group on cardio-oncology of the Korean society of echocardiography",
abstract = "Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.",
keywords = "Anti-cancer treatment, Cardio-oncology, Cardiovascular toxicity, Echocardiography",
author = "Hyungseop Kim and Chung, {Woo Baek} and Cho, {Kyoung Im} and Kim, {Bong Joon} and Seo, {Jeong Sook} and Seong-Mi Park and Kim, {Hak Jin} and Lee, {Ju Hee} and Kim, {Eun Kyoung} and Youn, {Ho Joong}",
year = "2018",
month = "1",
day = "1",
doi = "10.4250/jcu.2018.26.1.1",
language = "English",
volume = "26",
pages = "1--25",
journal = "Journal of Cardiovascular Imaging",
issn = "2586-7210",
publisher = "Korean Society of Echocardiography",
number = "1",

}

TY - JOUR

T1 - Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice

T2 - an opinion paper from the working group on cardio-oncology of the Korean society of echocardiography

AU - Kim, Hyungseop

AU - Chung, Woo Baek

AU - Cho, Kyoung Im

AU - Kim, Bong Joon

AU - Seo, Jeong Sook

AU - Park, Seong-Mi

AU - Kim, Hak Jin

AU - Lee, Ju Hee

AU - Kim, Eun Kyoung

AU - Youn, Ho Joong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.

AB - Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.

KW - Anti-cancer treatment

KW - Cardio-oncology

KW - Cardiovascular toxicity

KW - Echocardiography

UR - http://www.scopus.com/inward/record.url?scp=85046420017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046420017&partnerID=8YFLogxK

U2 - 10.4250/jcu.2018.26.1.1

DO - 10.4250/jcu.2018.26.1.1

M3 - Review article

AN - SCOPUS:85046420017

VL - 26

SP - 1

EP - 25

JO - Journal of Cardiovascular Imaging

JF - Journal of Cardiovascular Imaging

SN - 2586-7210

IS - 1

ER -